William Blair Issues Negative Outlook for Agenus Earnings

Agenus Inc. (NASDAQ:AGEN) – Equities researchers at William Blair lowered their Q4 2024 EPS estimates for Agenus in a report issued on Tuesday, November 12th. William Blair analyst M. Phipps now expects that the biotechnology company will post earnings of ($2.85) per share for the quarter, down from their prior estimate of ($2.81). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Agenus’ current full-year earnings is ($10.26) per share. William Blair also issued estimates for Agenus’ Q1 2025 earnings at ($2.90) EPS, Q2 2025 earnings at ($3.07) EPS, Q3 2025 earnings at ($3.22) EPS, Q4 2025 earnings at ($3.31) EPS, FY2025 earnings at ($12.51) EPS, FY2026 earnings at ($13.03) EPS and FY2027 earnings at ($12.97) EPS.

Other analysts have also recently issued reports about the stock. Robert W. Baird cut shares of Agenus from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $35.00 to $8.00 in a research note on Friday, July 19th. Jefferies Financial Group reissued a “hold” rating and set a $7.00 target price (up previously from $3.00) on shares of Agenus in a research report on Friday, July 19th. StockNews.com cut shares of Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. Baird R W lowered shares of Agenus from a “strong-buy” rating to a “hold” rating in a report on Friday, July 19th. Finally, HC Wainwright reduced their price target on shares of Agenus from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Tuesday. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.

Agenus Stock Down 8.6 %

NASDAQ:AGEN opened at $2.77 on Friday. The company’s 50 day moving average price is $4.74 and its 200-day moving average price is $8.77. Agenus has a 52 week low of $2.74 and a 52 week high of $19.69. The stock has a market cap of $59.75 million, a price-to-earnings ratio of -0.25 and a beta of 1.39.

Hedge Funds Weigh In On Agenus

Several large investors have recently added to or reduced their stakes in AGEN. Vanguard Group Inc. grew its stake in Agenus by 13.7% during the 1st quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock valued at $19,953,000 after acquiring an additional 4,134,232 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Agenus by 1,959.9% in the first quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock valued at $439,000 after acquiring an additional 720,629 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Agenus by 52.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 123,058 shares during the period. BNP Paribas Financial Markets raised its position in shares of Agenus by 81.3% during the first quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 84,477 shares during the period. Finally, Walleye Capital LLC acquired a new stake in shares of Agenus during the third quarter worth about $1,003,000. 61.46% of the stock is currently owned by institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.